Kushenol I combats ulcerative colitis via intestinal barrier preservation and gut microbiota optimization

Figure 9 Effects of kushenol I on intestinal barrier integrity and serum lipopolysaccharide levels in mice with ulcerative colitis. A: Alcian blue and periodic acid-Schiff (AB-PAS) staining were used to evaluate the impact of kushenol I (KSCI) on colonic barrier integrity (scale bar = 50 μm); B: Immunohistochemical analysis to assess the effects of KSCI intervention on the expression of the tight junction proteins occludin and zonula occludens-1 (ZO-1) (scale bar = 50 μm); C: Enzyme-linked immunosorbent assay kits were used to determine the influence of KSCI intervention on serum lipopolysaccharide (LPS) levels. Values are presented as the mean ± standard error of the mean (n = 6). ^aP < 0.05. ^cP < 0.001. P compared with the model group.